NANOMEDICINE IN THE FEMALE REPRODUCTIVE SYSTEM AND RELATED DISORDERS: A NARRATIVE REVIEW OF DIAGNOSTIC, THERAPEUTIC, AND TRANSLATIONAL APPLICATIONS

Nanotechnology is increasingly investigated across gynecologic imaging, drug and gene delivery, contraception, fertility preservation, and tissue repair. Objective: To summarize diagnostic and therapeutic applications of nanotechnology in gynecologic cancers, endometriosis, polycystic ovary syndrome (PCOS), uterine leiomyoma, menopause, contraception, and infertility, and to appraise safety and barriers to clinical translation. Methods: Narrative review of English-language literature indexed through August 2026, including peer-reviewed primary studies and prior reviews. No formal systematic review, meta-analysis, or quantitative pooling was performed. Results: Liposomes, polymeric, metal and metal-oxide nanoparticles, nanomicelles, and nucleic-acid nanocarriers have shown preclinical promise for cervical and ovarian tumor imaging, image-guided endometriosis treatment, targeted leiomyoma therapy, hormone delivery, contraception, and fertility preservation. Safety concerns center on size- and composition-dependent toxicity, systemic accumulation, and placental crossing; most applications remain preclinical. Conclusion: The strongest near-term potential lies in intraoperative tumor imaging, local vaginal drug delivery, sustained hormone delivery, and endometrial repair. Adoption will require standardized characterization, reproducible manufacturing, and long-term reproductive safety data.

1. Joudeh, N., & Linke, D. (2022). Nanoparticle classification, physicochemical properties, characterization, and applications: A comprehensive review for biologists. J Nanobiotechnology, 20(1), 262. 2. Beach, M. A., Nayanathara, U., Gao, Y., et al. (2024). Polymeric nanoparticles for drug delivery. Chem Rev, 124(9), 5505–5616. 3. Feynman, R. P. (1960). There's plenty of room at the bottom. Eng Sci, 23(5), 22–36. 4. Binnig, G., Rohrer, H., Gerber, C., & Weibel, E. (1982). Surface studies by scanning tunneling microscopy. Phys Rev Lett, 49(1), 57–61. 5. Binnig, G., Quate, C. F., & Gerber, C. (1986). Atomic force microscope. Phys Rev Lett, 56(9), 930–933. 6. Luo, X., Jia, K., Xing, J., & Yi, J. (2024). The utilization of nanotechnology in the female reproductive system and related disorders. Heliyon, 10(3), e25477. 7. Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. Bioeng Transl Med, 4(3), e10143. 8. Pavelić, K., Kraljević Pavelić, S., Bulog, A., et al. (2023). Nanoparticles in medicine: Current status in cancer treatment. Int J Mol Sci, 24(16), 12827. 9. Fathi, P., Knox, H. J., Sar, D., et al. (2019). Biodegradable biliverdin nanoparticles for efficient photoacoustic imaging. ACS Nano, 13(7), 7690–7704. 10. Lou, X., Zhao, Z., & Tang, B. Z. (2016). Organic dots based on AIEgens for two-photon fluorescence bioimaging. Small, 12(47), 6430–6450. 11. Zhang, L., Chen, Q., Zou, X., et al. (2019). Intelligent protein-coated bismuth sulfide and manganese oxide nanocomposites obtained by biomineralization for multimodal imaging-guided enhanced tumor therapy. J Mater Chem B, 7(34), 5170–5181. 12. Moses, A. S., Taratula, O. R., Lee, H., et al. (2020). Nanoparticle-based platform for activatable fluorescence imaging and photothermal ablation of endometriosis. Small, 16(18), e1906936. 13. Lee, H. J., Lee, H. J., Lee, J. M., Chang, Y., & Woo, S. T. (2012). Ultrasmall superparamagnetic iron oxides enhanced MR imaging in rats with experimentally induced endometriosis. Magn Reson Imaging, 30(6), 860–868. 14. Zhang, Q., Li, H., Xu, L., et al. (2026). Engineering anti-MMP-9 peptide-modified nanoparticles for precision MRI diagnosis of endometriosis. Mol Imaging Biol, 28(2), 334–346. 15. Koduru, R., Maity, S., Das, D., Pamuru, R. R., Mohammed, A., & Mohiddin, G. J. (2026). Nanotechnology for reproductive healthcare: A comprehensive review. J Nanobiotechnology, 24(1), 262. 16. Sakaguchi, N., Kusamoto, A., Harada, M., et al. (2026). Butyric acid-based self-assembling nanoparticles: A potential strategy to prevent development of polycystic ovary syndrome. Mol Hum Reprod, 32(1), gaag013. 17. Park, Y., Demessie, A. A., Luo, A., et al. (2022). Targeted nanoparticles with high heating efficiency for the treatment of endometriosis with systemically delivered magnetic hyperthermia. Small, 18(24), e2107808. 18. Egorova, A., Petrosyan, M., Maretina, M., et al. (2023). iRGD-targeted peptide nanoparticles for anti-angiogenic RNAi-based therapy of endometriosis. Pharmaceutics, 15(8), 2108. 19. Chaudhury, K., Babu, K. N., Singh, A. K., et al. (2013). Mitigation of endometriosis using regenerative cerium oxide nanoparticles. Nanomedicine, 9(3), 439–448. 20. Avila-Tavares, R., Gibran, L., Brito, L. G. O., et al. (2024). Pilot study of treatment of patients with deep infiltrative endometriosis with methotrexate carried in lipid nanoparticles. Arch Gynecol Obstet, 309(2), 659–667. 21. Zhu, S., Zhang, J., Xue, N., et al. (2023). Highly specific neutrophil-mediated delivery of albumin nanoparticles to ectopic lesion for endometriosis therapy. J Nanobiotechnol, 21(1), 81. 22. Pareek, S., Jain, U., Balayan, S., & Chauhan, N. (2022). Ultra-sensitive nano-molecular imprinting polymer-based electrochemical sensor for follicle-stimulating hormone (FSH) detection. Biochem Eng J, 180, 108329. 23. Deswal, R., Narwal, V., Dang, A. S., & Pundir, C. S. (2019). An ultrasensitive electrochemical immunosensor for detection of sex hormone binding globulin. Microchem J, 149, 104010. 24. Alwan, S. H., & Al-Saeed, M. H. (2023). Silver nanoparticles biofabricated from Cinnamomum zeylanicum reduce IL-6, IL-18, and TNF-α in female rats with polycystic ovarian syndrome. Int J Fertil Steril, 17(1), 80–84. 25. Raja, M. A., Maldonado, M., Chen, J., Zhong, Y., & Gu, J. (2021). Development and evaluation of curcumin encapsulated self-assembled nanoparticles as potential remedial treatment for PCOS in a female rat model. Int J Nanomedicine, 16, 6231–6247. 26. Simon, J. A., & Estrasorb Study Group. (2006). Estradiol in micellar nanoparticles: The efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause, 13(2), 222–231. 27. Botelho, M. A., Queiroz, D. B., Barros, G., et al. (2014). Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: A confocal Raman spectroscopy study. Clinics (Sao Paulo), 69(2), 75–82. 28. Ye, T., Zhong, X., Wang, S., et al. (2026). Targeting and antioxidant surface-engineered mesenchymal stromal cells for enhanced erectile dysfunction therapy. Nat Commun, 17, 8426. 29. Wang, S., Wang, Z., Shen, Z., et al. (2024). Magnetic soft microrobots for erectile dysfunction therapy. Proc Natl Acad Sci U S A, 121(49), e2407809121. 30. Zhang, J., Zhao, D., Zang, Z., Ruan, Z., Fu, Q., & Zhang, K. (2024). miR-200a-3p-enriched MSC-derived extracellular vesicles reverse erectile function in diabetic rats by targeting Keap1. Biomed Pharmacother, 177, 116964. 31. Fu, Q., Song, L., Li, J., et al. (2023). Biodegradable nano black phosphorus based SDF1-α delivery system ameliorates erectile dysfunction in a cavernous nerve injury rat model by recruiting endogenous stem/progenitor cells. J Nanobiotechnology, 21, 487. 32. Uthaman, S., Huh, K. M., & Park, I. K. (2018). Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomater Res, 22, 22. 33. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov, 20(2), 101–124. 34. Stater, E. P., Sonay, A. Y., Hart, C., & Grimm, J. (2021). The ancillary effects of nanoparticles and their implications for nanomedicine. Nat Nanotechnol, 16(11), 1180–1194. 35. Tarighatnia, A., Fouladi, M. R., Nader, N. D., Aghanejad, A., & Ghadiri, H. (2022). Recent trends of contrast agents in ultrasound imaging: A review of the classifications and applications. Mater Adv, 3(9), 3726–3741. 36. Zhao, Z., Wang, D., & Li, Y. (2023). Versatile biomimetic nanomedicine for treating cancer and inflammation disease. Med Rev (2021), 3(2), 123–151. 37. Torabi, M., Aghanejad, A., Savadi, P., Barzegari, A., Omidi, Y., & Barar, J. (2023). Targeted delivery of sunitinib by MUC-1 aptamer-capped magnetic mesoporous silica nanoparticles. Molecules, 28(1), 233. 38. Jin, M., Liu, B., Zhang, Z., et al. (2024). Catechin-functionalized cationic lipopolymer based multicomponent nanomicelles for lung-targeting delivery. Adv Mater, 36(17), e2302985. 39. Wang, Y., Sun, B., Hao, Z., & Zhang, J. (2023). Advances in organic-inorganic hybrid latex particles via in situ emulsion polymerization. Polymers (Basel), 15(14), 3092. 40. Aloisi, M., Rossi, G., Colafarina, S., Guido, M., Cecconi, S., & Poma, A. G. M. (2022). The impact of metal nanoparticles on female reproductive system: Risks and opportunities. Int J Environ Res Public Health, 19(21), 13748. 41. Lu, W., Chen, T., Xiao, D., Qin, X., Chen, Y., & Shi, S. (2023). Application and prospects of nucleic acid nanomaterials in tumor therapy. RSC Adv, 13(37), 26288–26301. 42. Garzon, S., Laganà, A. S., Barra, F., et al. (2021). Novel drug delivery methods for improving efficacy of endometriosis treatments. Expert Opin Drug Deliv, 18(3), 355–367. 43. Yang, S., Chen, Y., Ahmadie, R., & Ho, E. A. (2013). Advancements in the field of intravaginal siRNA delivery. J Control Release, 167(1), 29–39. 44. Shalaby, S. M., Khater, M. K., Perucho, A. M., et al. (2016). Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril, 105(6), 1638–1648.e8. 45. Borahay, M. A., Vincent, K., Motamedi, M., et al. (2021). Liposomal 2-methoxyestradiol nanoparticles for treatment of uterine leiomyoma in a patient-derived xenograft mouse model. Reprod Sci, 28(1), 271–277. 46. Al Enazy, S. A., Kirschen, G. W., Vincent, K., et al. (2023). PEGylated polymeric nanoparticles loaded with 2-methoxyestradiol for the treatment of uterine leiomyoma in a patient-derived xenograft mouse model. J Pharm Sci, 112(9), 2552–2560. 47. El Sabeh, M., Vincent, K. L., Afrin, S., et al. (2022). Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: A pilot study. J Obstet Gynaecol, 42(6), 2139–2143. 48. Shtykalova, S., Egorova, A., Maretina, M., et al. (2022). Magnetic nanoparticles as a component of peptide-based DNA delivery system for suicide gene therapy of uterine leiomyoma. Bioengineering (Basel), 9(3), 112. 49. Abdelgader, A., Govender, M., Kumar, P., & Choonara, Y. E. (2023). Intravaginal drug delivery systems to treat the genitourinary syndrome of menopause: Towards the design of safe and efficacious estrogen-loaded prototypes. J Pharm Sci, 112(6), 1566–1585. 50. Cai, G., Hou, Z., Sun, W., et al. (2022). Recent developments in biomaterial-based hydrogel as the delivery system for repairing endometrial injury. Front Bioeng Biotechnol, 10, 894252. 51. Herrara, V., Tarab-Ravski, D., Chauhan, S. C., et al. (2025). Nanotechnology strategies for endometrium health: Are we on the right track? Bioact Mater, 54, 423–449. 52. Abbasi, S., Ortiz, J., Bockley, K., et al. (2026). Spatiotemporal targeting of messenger RNA lipid nanoparticles to the endometrium for the treatment of reproductive disorders. Nat Nanotechnol, 21(3), 467–477. 53. Oster, G. K. (1972). Chemical reactions of the copper intrauterine device. Fertil Steril, 23(1), 18–23. 54. Wen, X., Wang, Z., Lin, J., et al. (2026). Nanotechnology in reproductive medicine: From gamete engineering to precision therapeutics. RSC Adv, 16(35), 34319–34338. 55. Roshanfekr Rad, M., Nejati, V., Razi, M., & Najafi, G. (2020). Nano-micelle curcumin; A hazardous and/or boosting agent? Relation with oocyte in-vitro maturation and pre-implantation embryo development in rats. Iran J Pharm Res, 19(2), 242–250. 56. Xu, Y., Ye, Z., Hu, S., et al. (2026). A hollow MnO2 nanozymes empowered injectable hydrogel for intrauterine adhesion therapy by alleviating oxidative stress and promoting endometrial repair. Biomater Sci, 14(9), 2361–2371. 57. Zhen, S., Liu, Y., Lu, J., et al. (2020). Human papillomavirus oncogene manipulation using clustered regularly interspaced short palindromic repeats/Cas9 delivered by pH-sensitive cationic liposomes. Hum Gene Ther, 31(5–6), 309–324. 58. Rosenblum, D., Gutkin, A., Kedmi, R., et al. (2020). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv, 6(47), eabc9450. 59. Chaudhary, N., Newby, A. N., Arral, M. L., et al. (2024). Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes. Proc Natl Acad Sci U S A, 121, e2307810121. 60. Yang, H., Liu, C., Yang, D., Zhang, H., & Xi, Z. (2009). Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: The role of particle size, shape and composition. J Appl Toxicol, 29(1), 69–78. 61. Sharifi, S., Behzadi, S., Laurent, S., Forrest, M. L., Stroeve, P., & Mahmoudi, M. (2012). Toxicity of nanomaterials. Chem Soc Rev, 41(6), 2323–2343. 62. Yadav, K., & Sharma, R. (2026). Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern. Reprod Toxicol, 139, 109103. 63. Santacruz-Márquez, R., Souza, P. V., Scarano, W. R., & Flaws, J. A. (2026). Impact of nanoparticles and nanoplastics on female reproductive health. Biol Reprod, ioag036. Published online February 10, 2026. 64. Iqbal, Z., & Dilnawaz, F. (2019). Nanocarriers for vaginal drug delivery. Recent Pat Drug Deliv Formul, 13(1), 3–15. 65. Bartusik-Aebisher, D., Wilk, I., & Aebisher, D. (2026). Nanomedicine in ovarian cancer: Advances in imaging, targeted delivery, and theranostic therapeutic platforms. Cancers (Basel), 18(1), 86. 66. Chen, H. Y., Li, N., Zhu, X. D., et al. (2026). Nanomaterial platforms for endometriosis: A systematic review. Curr Med Sci. Published online August 21, 2026. https://doi.org/10.1007/s11596-026-00239-z Downloads Published How to Cite Issue Section License I (we) submit this article which is original and unpublished, of my (our) own authorship, to the evaluation of the Veredas do Direito Journal, and agree that the related copyrights will become exclusive property of the Journal, being prohibited any partial or total copy in any other part or other printed or online communication vehicle dissociated from the Veredas do Direito Journal, without the necessary and prior authorization that should be requested in writing to Editor in Chief. I (we) also declare that there is no conflict of interest between the articles theme, the author (s) and enterprises, institutions or individuals. I (we) recognize that the Veredas do Direito Journal is licensed under a CREATIVE COMMONS LICENSE. Licença Creative Commons Attribution 3.0